Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
Trial details
- Registry ID
- NCT06298955
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as OMS906
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaNCT06298955 | Omeros Corporation | Phase 2 | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNNCT06209736 | Omeros Corporation | Phase 2 | Terminated | 2026-04-14Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |